Axsome Therapeutics Inc

Regional Account Manager- Neurology (Sunbelt Region Based Candidates)

United States

Not SpecifiedCompensation
Senior (5 to 8 years), Junior (1 to 2 years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceuticals, Biotechnology, HealthcareIndustries

Requirements

Candidates must possess a Bachelor’s degree, with preferred degrees in life sciences, business, or healthcare, and a minimum of 5 years of pharmaceutical, biotech, or healthcare sales experience, including at least 3 years of experience in rare disease or orphan drug sales. Proven track record of exceeding sales targets and successfully managing a territory is essential, along with experience selling high-cost products through specialty pharmacies.

Responsibilities

The Regional Account Manager will be responsible for representing PTC’s products to medical professionals specializing in neurological diseases and Friedreich’s Ataxia (FA) within their assigned region, generating sales, communicating product benefits, building relationships, educating healthcare staff, and identifying new opportunities. They will also implement marketing strategies, collaborate with internal and external teams, develop business partnerships, identify key treatment centers, cultivate relationships with patient advocacy groups, employ a consultative sales approach, address product access issues, and perform additional tasks as needed.

Skills

Pharmaceutical sales
Biotech sales
Healthcare sales
Specialized clinic experience
Hospital and academic center sales
Account management
Technical data analysis
Strategic solutions development

Axsome Therapeutics Inc

Develops therapies for CNS disorders

About Axsome Therapeutics Inc

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

Key Metrics

New York City, New YorkHeadquarters
2012Year Founded
$430.7MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees

Benefits

Performance Bonus
Company Equity

Risks

Increased competition from companies like Compass Pathways in the CNS market.
Potential delays in AXS-07 launch amid growing market anticipation.
Departure of key personnel like Lori Englebert may impact strategic direction.

Differentiation

Axsome focuses on CNS disorders with limited current treatment options.
AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.
Axsome's balanced portfolio includes both clinical and research stage products.

Upsides

FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.
Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.
Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

Land your dream remote job 3x faster with AI